Evidence map›Paper›PMID 23235665›Full record

SynthesisThe Cochrane database of systematic reviews2012

Optimal loading dose of warfarin for the initiation of oral anticoagulation.

Kamal R Mahtani, Carl J Heneghan, David Nunan, Clare Bankhead, David Keeling, Alison M Ward, Sian E Harrison, Nia W Roberts, F D Richard Hobbs, Rafael Perera

Registry-linked trialAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in The Cochrane database of systematic reviews, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04235569 (Evaluation of Warfarin Initiation at 3mg Versus 5mg for Anticoagulation of Mechanical Mitral Valve Replacement Patients), which is not on this map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04235569 phase4completednot on this mapstarted 2018, after this paper: background citation

Evaluation of Warfarin Initiation at 3mg Versus 5mg for Anticoagulation of Mechanical Mitral Valve Replacement Patients

TypeinterventionalSponsorSarah Sabry HashemRan2018 to 2019Enrolled50ConditionsMitral Valve DiseaseArmsWarfarin Sodium 5 MG, Warfarin Sodium 3 MG, Enoxaparin Sodium 100 MG/ML Prefilled Syringe
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Warfarin initiation nomograms for venous thromboembolism.The Cochrane database of systematic reviews · 2016
    Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Semi-empirical anticoagulation model (SAM): INR monitoring during Warfarin therapy.Journal of pharmacokinetics and pharmacodynamics · 2022
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kamal R MahtaniDepartment of Primary Care Health Sciences, University of Oxford, Oxford, UK. kamal.mahtani@phc.ox.ac.uk.
Carl J Heneghan
David Nunan
Clare Bankhead
David Keeling
Alison M Ward
Sian E Harrison
Nia W Roberts
F D Richard Hobbs
Rafael Perera

Funding

Medical Research Council G9900264
6 · The paper itself

Abstract

backgroundWarfarin is used as an oral anticoagulant. However, there is wide variation in patient response to warfarin dose. This variation, as well as the necessity of keeping within a narrow therapeutic range, means that selection of the correct warfarin dose at the outset of treatment is not straightforward.

objectivesTo assess the effectiveness of different initiation doses of warfarin in terms of time in-range, time to INR in-range and effect on serious adverse events. SEARCH

methodsWe searched CENTRAL, DARE and the NHS Health economics database on The Cochrane Library (2012, Issue 4); MEDLINE (1950 to April 2012) and EMBASE (1974 to April 2012). SELECTION CRITERIA: All randomised controlled trials which compared different initiation regimens of warfarin. DATA COLLECTION AND ANALYSIS: Review authors independently assessed studies for inclusion. Authors also assessed the risk of bias and extracted data from the included studies. MAIN

resultsWe identified 12 studies of patients commencing warfarin for inclusion in the review. The overall risk of bias was found to be variable, with most studies reporting adequate methods for randomisation but only two studies reporting adequate data on allocation concealment. Four studies (355 patients) compared 5 mg versus 10 mg loading doses. All four studies reported INR in-range by day five. Although there was notable heterogeneity, pooling of these four studies showed no overall difference between 5 mg versus 10 mg loading doses (RR 1.17, 95% CI 0.77 to 1.77, P = 0.46, I(2) = 83%). Two of these studies used two consecutive INRs in-range as the outcome and showed no difference between a 5 mg and 10 mg dose by day five (RR 0.86, 95% CI 0.62 to 1.19, P = 0.37, I(2 )= 22%); two other studies used a single INR in-range as the outcome and showed a benefit for the 10 mg initiation dose by day 5 (RR 1.49, 95% CI 1.01 to 2.21, P = 0.05, I(2 )= 72%). Two studies compared a 5 mg dose to other doses: a 2.5 mg initiation dose took longer to achieve the therapeutic range (2.7 versus 2.0 days; P < 0.0001), but those receiving a calculated initiation dose achieved a target range quicker (4.2 days versus 5 days, P = 0.007). Two studies compared age adjusted doses to 10 mg initiation doses. More elderly patients receiving an age adjusted dose achieved a stable INR compared to those receiving a 10 mg initial dose (and Fennerty regimen). Four studies used genotype guided dosing in one arm of each trial. Three studies reported no overall differences; the fourth study, which reported that the genotype group spent significantly more time in-range (P < 0.001), had a control group whose INRs were significantly lower than expected. No clear impacts from adverse events were found in either arm to make an overall conclusion. AUTHORS'

conclusionsThe studies in this review compared loading doses in several different situations. There is still considerable uncertainty between the use of a 5 mg and a 10 mg loading dose for the initiation of warfarin. In the elderly, there is some evidence that lower initiation doses or age adjusted doses are more appropriate, leading to fewer high INRs. However, there is insufficient evidence to warrant genotype guided initiation.

Indexed as

Age FactorsAnticoagulantsHumansInternational Normalized RatioRandomized Controlled Trials as TopicWarfarinAnticoagulantsWarfarin

Identifiers

PMID23235665
PMCPMC8454262

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.